United Therapeutics used Citibank for accelerated share repurchases while its products are pending review for market approval by the FDA.
1 report, 1 independent
Updated Sep 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
United Therapeutics used Citibank for accelerated share repurchases while its products are pending review for market approval by the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Acurx Pharmaceuticals trades on NASDAQ and is receiving FDA guidance supporting its potential approval pathway.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- FDA and Pfizer are seeking regulatory approval for their products.